3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
326
Gynecologic
15
Thoracic
10
Gastrointestinal
9
Genitourinary
8
Head & Neck
4
Sarcoma
3
Endocrine
3
CNS
2
Other solid neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Multiple Endocrine Neoplasia Type 1
5
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Neoplasms by Site
1
Hyperglycemia
1
Breast Diseases
1
Interventions
selpercatinib
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
ribociclib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Cyclophosphamide
2
Alpelisib
2
vandetanib
1
tivozanib
1
tipifarnib
1
temsirolimus
1
romidepsin
1
pembrolizumab
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
fludarabine phosphate
1
fludarabine
1
exemestane
1
entrectinib
1
entinostat
1
avelumab
1
atezolizumab
1
alectinib
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Fulvestrant
×
Endocrine
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA